## PATIENT

| | |
|---|---|
| Name: | Lynx Dx Patient |
| DOB: | 10/23/1959 |
| MRN: | REQ000000 |

## SPECIMEN

| | |
|---|---|
| Collection Date: | 01/08/2024 |
| Receive Date: | 01/10/2024 |
| Result Date: | 01/15/2024 |
| Order Number: | SO00000 |

## ORDERING PHYSICIAN

| | |
|---|---|
| Physician: | Dr. John Smith |
| Clinic: | Urology Office |
| Address: | 123 Main Street |
| | Anywhere, US 12345 |

## RISK THRESHOLD

| | |
|---|---|
| Low Risk: | 0% – 14.5% |
| Increasing Risk: | ≥ 14.6% |



YOUR RESULTS
## 8.2%

**Risk category:** Low

**Likelihood of Clinically Significant Cancer Grade Group 2 or higher:** 8.2%

---

**Test Description:**

MyProstateScore 2.0 (MPS2) measures 18 urinary biomarkers* to predict the percent likelihood of detecting clinically significant prostate cancer (Grade Group [GG] ≥2, also termed Gleason score ≥7) on biopsy. The model used to generate the result, and the threshold for Low Risk versus Increasing Risk, are specific to clinical context and take into consideration whether the patient has had a prior biopsy and whether MPS2 is run as a biomarker-only test or inclusive of clinical risk factors. For the model used for this report, a score of 14.5% represents the threshold between Low Risk and Increasing Risk. At this threshold for the applied model, MPS2 has the following performance numbers: Sensitivity 92% NPV 94%.

*T2:ERG, SCHLAP1, OR51E2, APOC1, PCAT14, CAMKK2, PCA3, NKAIN1, B3GNT6, TFF3, SPON2, PCGEM1, TRGV9, TMSB15A, ERG, KLK3, KLK4, HOXC6

**Disclaimer:**

This test was developed, and its performance characteristics determined by Lynx Dx, Inc. This test is intended to assist clinical decision making related to the need for a prostate biopsy. Definitive diagnosis of prostate cancer can only be confirmed through a prostate biopsy. This test has not been cleared nor approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendment of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

**CLIA Director:** Dr. John Kitchen; **CLIA Number:** 23D2182199
**Performing site:** Lynx Dx, Inc., 5230 S. State Rd., Ann Arbor, MI 48018

## PATIENT

| | |
|---|---|
| Name: | Lynx Dx Patient |
| DOB: | 12/09/78 |
| MRN: | REQ000000 |

## SPECIMEN

| | |
|---|---|
| Collection Date: | 01/20/2024 |
| Receive Date: | 01/22/2024 |
| Result Date: | 01/27/2024 |
| Order Number: | SO00000 |

## ORDERING PHYSICIAN

| | |
|---|---|
| Physician: | Dr. John Smith |
| Clinic: | Urology Office |
| Address: | 123 Main Street |
| | Anywhere, US 12345 |

## RISK THRESHOLD

| | |
|---|---|
| Low Risk: | 0% – 5.8% |
| Increasing Risk: | ≥ 5.9% |



YOUR RESULTS
**3.6%**

**Risk category:** Low

**Likelihood of Clinically Significant Cancer Grade Group 2 or higher:** 3.6%

---

**Test Description:**

MyProstateScore 2.0 (MPS2) measures 18 urinary biomarkers* to predict the percent likelihood of detecting clinically significant prostate cancer (Grade Group [GG] ≥2, also termed Gleason score ≥7) on biopsy. The model used to generate the result, and the threshold for Low Risk versus Increasing Risk, are specific to clinical context and take into consideration whether the patient has had a prior biopsy and whether MPS2 is run as a biomarker-only test or inclusive of clinical risk factors. For the model used for this report, a score of 5.8% represents the threshold between Low Risk and Increasing Risk. At this threshold for the applied model, MPS2 has the following performance numbers: Sensitivity 94% NPV 99%.

*T2:ERG, SCHLAP1, OR51E2, APOC1, PCAT14, CAMKK2, PCA3, NKAIN1, B3GNT6, TFF3, SPON2, PCGEM1, TRGV9, TMSB15A, ERG, KLK3, KLK4, HOXC6

**Disclaimer:**

**CLIA Director:** Dr. John Kitchen; **CLIA Number:** 23D2182199
**Performing site:** Lynx Dx, Inc., 5230 S. State Rd., Ann Arbor, MI 48018